Apeximmune Therapeutics engages in the discovery and development of novel biologics that modulate the immune system.
Apeximmune Therapeutics has raised $21.3M in total funding. The most recent round was Series A. The last funding was announced in March 2025.
Apeximmune Therapeutics's investors include PharmaEssentia, DCI Partners, Taya Venture Capital, Huahai US, Hercules Bioventure Partners.
Apeximmune Therapeutics is headquartered in Burlingame, United States.
Apeximmune Therapeutics engages in the discovery and development of novel biologics that modulate the immune system.
Apeximmune Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Apeximmune Therapeutics — Funding & Investors." VCBacked, March 31, 2025, https://www.vcbacked.co/company/apeximmune-therapeutics. Accessed August 13, 2026.
VCBacked. (2025). Apeximmune Therapeutics — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/apeximmune-therapeutics
{{cite web |title=Apeximmune Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/apeximmune-therapeutics |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated